Patient investors who wanted the monthly sell-off to unfold might find rewards this month.
Novo Nordisk (NVO), an obesity drug manufacturer, resumed its yearlong downtrend. NVO stock briefly traded above $60, only to fade. Shareholders continued to lose confidence in its management.
Novo lost 15% in February when it forecast profits would decline this year. It has pricing pressures that will cut its profitability. Novo negotiated unfavorable drug prices with the U.S. government. It also faces patent expiry for semaglutide, a key ingredient, in some of its markets.
Lilly (LLY) shares traded flat for the month.
Flutter (FLUT), which runs FanDual, slumped, losing 37.5% in the month. The firm issued a revenue forecast of $18.4 billion for 2026. Management identified a slowdown in betting. The industry also increased its promotional activity, worsening competition. DraftKings (DKNG) lost 21% in the month.
South Korean e-commerce firm Coupang (CPNG) dropped by 6.2% in February. It recorded a one-cent EPS loss in Q4.
Duolingo (DUOL), once a high-flyer during the pandemic in 2021, lost 31% of its value. The profit margins will worsen this year. Management prioritized growing daily active user health instead of profitability. Expect bookings to slow down to an 11% rate. This is half the historical 20% growth rate that the language app supplier enjoyed.
Duolingo aims to grow its DAU to 100 million by 2028.
Related Stories
